Precision therapy for a medically actionable ATP1A3 variant from a genomic medicine program in an underserved population.
ATP1A3
alternating hemiplegia of childhood
genomics
health care equity
underserved population
Journal
Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758
Informations de publication
Date de publication:
23 Aug 2023
23 Aug 2023
Historique:
revised:
21
06
2023
received:
08
03
2023
accepted:
08
08
2023
medline:
24
8
2023
pubmed:
24
8
2023
entrez:
24
8
2023
Statut:
aheadofprint
Résumé
Genomic medicine is revolutionizing the diagnosis of rare diseases, but the implementation has not benefited underrepresented populations to the same degree. Here, we report the case of a 7-year-old boy with hypotonia, global developmental delay, strabismus, seizures, and previously suspected mitochondrial myopathy. This proband comes from an underrepresented minority and was denied exome sequencing by his public insurance. After informed consent was obtained, buccal cells from the proband were collected and whole exome sequencing was performed. Illumina Dragen and Emedgene software was used to analyze the data at Baylor Genetics. The variants were further intepreted according to ACMG guidelines and the patient's phenotype. Through whole-exome sequencing (WES) under the Community Texome project, he was found to have a heterozygous de novo pathogenic variant in the ATP1A3 gene located on chromosome 19q13. In retrospect, his symptomatology matches the known medical conditions associated with the ATP1A3 gene namely Alternating Hemiplegia of Childhood 2 (AHC), a rare autosomal dominant disorder with an incidence of 1 in one million. His single nucleotide variant, (c.2401G>A, p.D801N), is predicted to be damaging. The specific amino acid change p.D801N has been previously reported in ClinVar along with the allelic variant p.D801Y and both are considered pathogenic. The identification of this variant altered medical management for this patient as he was started on a calcium antagonist and has reported no further hemiplegic episodes. This case illustrates the value of implementing genomic medicine for precision therapy in underserved populations.
Sections du résumé
BACKGROUND
BACKGROUND
Genomic medicine is revolutionizing the diagnosis of rare diseases, but the implementation has not benefited underrepresented populations to the same degree. Here, we report the case of a 7-year-old boy with hypotonia, global developmental delay, strabismus, seizures, and previously suspected mitochondrial myopathy. This proband comes from an underrepresented minority and was denied exome sequencing by his public insurance.
METHODS
METHODS
After informed consent was obtained, buccal cells from the proband were collected and whole exome sequencing was performed. Illumina Dragen and Emedgene software was used to analyze the data at Baylor Genetics. The variants were further intepreted according to ACMG guidelines and the patient's phenotype.
RESULTS
RESULTS
Through whole-exome sequencing (WES) under the Community Texome project, he was found to have a heterozygous de novo pathogenic variant in the ATP1A3 gene located on chromosome 19q13.
CONCLUSION
CONCLUSIONS
In retrospect, his symptomatology matches the known medical conditions associated with the ATP1A3 gene namely Alternating Hemiplegia of Childhood 2 (AHC), a rare autosomal dominant disorder with an incidence of 1 in one million. His single nucleotide variant, (c.2401G>A, p.D801N), is predicted to be damaging. The specific amino acid change p.D801N has been previously reported in ClinVar along with the allelic variant p.D801Y and both are considered pathogenic. The identification of this variant altered medical management for this patient as he was started on a calcium antagonist and has reported no further hemiplegic episodes. This case illustrates the value of implementing genomic medicine for precision therapy in underserved populations.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2272Subventions
Organisme : NHGRI NIH HHS
ID : R01HG011795
Pays : United States
Informations de copyright
© 2023 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Références
Capuano, A., Garone, G., Tiralongo, G., & Graziola, F. (2020). Alternating hemiplegia of childhood: Understanding the genotype-phenotype relationship of ATP1A3 variations. The Application of Clinical Genetics, 13(March), 71-81.
Carecchio, M., Zorzi, G., Ragona, F., Zibordi, F., & Nardocci, N. (2018). ATP1A3-related disorders: An update. European Journal of Paediatric Neurology: EJPN: Official Journal of the European Paediatric Neurology Society, 22(2), 257-263.
Cordani, R., Stagnaro, M., Pisciotta, L., Tiziano, F. D., Calevo, M. G., Nobili, L., I.B.AHC Consortium, & De Grandis, E. (2021). Alternating hemiplegia of childhood: Genotype-phenotype correlations in a cohort of 39 Italian patients. Frontiers in Neurology, 12(April), 658451.
Fraiman, Y. S., & Wojcik, M. H. (2021). The influence of social determinants of health on the genetic diagnostic odyssey: Who remains undiagnosed, why, and to what effect? Pediatric Research, 89(2), 295-300.
Goldenberg, A. J., Marshall, P. A., & Sharp, R. R. (2013). Next-generation disadvantages: Identifying potential barriers to integrating genomics into underserved medical settings. Personalized Medicine, 10(7), 623-625.
Hartin, S. N., Means, J. C., Alaimo, J. T., & Younger, S. T. (2020). Expediting rare disease diagnosis: A call to bridge the gap between clinical and functional genomics. Molecular Medicine (Cambridge, Mass.), 26(1), 117.
Heinzen, E. L., Arzimanoglou, A., Brashear, A., Clapcote, S. J., Gurrieri, F., Goldstein, D. B., Jóhannesson, S. H., Mikati, M. A., Neville, B., Nicole, S., Ozelius, L. J., Poulsen, H., Schyns, T., Sweadner, K. J., van den Maagdenberg, A., Vilsen, B., & ATP1A3 Working Group. (2014). Distinct neurological disorders with ATP1A3 mutations. Lancet Neurology, 13(5), 503-514.
Heinzen, E. L., Swoboda, K. J., Hitomi, Y., Gurrieri, F., Nicole, S., de Vries, B., Tiziano, F. D., Fontaine, B., Walley, N. M., Heavin, S., Panagiotakaki, E., European Alternating Hemiplegia of Childhood (AHC) Genetics Consortium; Biobanca e Registro Clinico per l'Emiplegia Alternante (I.B.AHC) Consortium; European Network for Research on Alternating Hemiplegia (ENRAH) for Small and Medium-sized Enterpriese (SMEs) Consortium, Fiori, S., Abiusi, E., Di Pietro, L., Sweney, M. T., Newcomb, T. M., Viollet, L., Huff, C., … Goldstein, D. B. (2012). De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nature Genetics, 44(9), 1030-1034.
Hunanyan, A. S., Fainberg, N. A., Linabarger, M., Eric Arehart, A., Leonard, S., Adil, S. M., Helseth, A. R., Swearingen, A. K., Forbes, S. L., Rodriguiz, R. M., Rhodes, T., Yao, X., Kibbi, N., Hochman, D. W., Wetsel, W. C., Hochgeschwender, U., & Mikati, M. A. (2015). Knock-in mouse model of alternating hemiplegia of childhood: Behavioral and electrophysiologic characterization. Epilepsia, 56(1), 82-93.
Kusunoki, S., Kido, J., Momosaki, K., Sawada, T., Kashiki, T., Matsumoto, S., & Nakamura, K. (2020). Effect of flunarizine on alternating hemiplegia of childhood in a patient with the p.E815K mutation in ATP1A3: A case report. Case Reports in Neurology, 12(3), 299-306.
Neville, B. G. R., & Ninan, M. (2007). The treatment and management of alternating hemiplegia of childhood. Developmental Medicine and Child Neurology, 49(10), 777-780.
Panagiotakaki, E., De Grandis, E., Stagnaro, M., Heinzen, E. L., Fons, C., Sisodiya, S., de Vries, B., Goubau, C., Weckhuysen, S., Kemlink, D., Scheffer, I., Lesca, G., Rabilloud, M., Klich, A., Ramirez-Camacho, A., Ulate-Campos, A., Campistol, J., Giannotta, M., Moutard, M. L., … Italian IBAHC Consortium; French AHC Consortium; International AHC Consortium. (2015). Clinical profile of patients with ATP1A3 mutations in alternating hemiplegia of childhood-a study of 155 patients. Orphanet Journal of Rare Diseases, 10(1), 123.
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., Voelkerding, K., Rehm, H. L., & ACMG Laboratory Quality Assurance Committee. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 17(5), 405-424.
Rosewich, H., Thiele, H., Ohlenbusch, A., Maschke, U., Altmüller, J., Frommolt, P., Zirn, B., Ebinger, F., Siemes, H., Nürnberg, P., Brockmann, K., & Gärtner, J. (2012). Heterozygous De-novo mutations in ATP1A3 in patients with alternating hemiplegia of childhood: A whole-exome sequencing gene-identification study. Lancet Neurology, 11(9), 764-773.
Salles, P. A., Mata, I. F., Brünger, T., Lal, D., & Fernandez, H. H. (2021). ATP1A3-related disorders: An ever-expanding clinical Spectrum. Frontiers in Neurology, 12(April), 637890.
Upadhyay, S. K., & Ali, S. M. (2018). Molecular recognition of flunarizine dihydrochloride and β-cyclodextrin inclusion complex by NMR and computational approaches. Chemistry Central Journal, 12(1), 33. https://doi.org/10.1186/s13065-018-0395-4